Taťána Gazárková is currently a&nbsp;postdoctoral fellow in the Laboratory of Antibiotic Resistance and Microbial Metabolomics. During her doctoral studies, she focused on chromatography and mass spectrometry. Recently, she was awarded second place in the “Sanofi Prize for Pharmacy 2026” competition.Taťána Gazárková is currently a&nbsp;postdoctoral fellow in the Laboratory of Antibiotic Resistance and Microbial Metabolomics. During her doctoral studies, she focused on chromatography and mass spectrometry. Recently, she was awarded second place in the “Sanofi Prize for Pharmacy 2026” competition, which is awarded by the French Embassy in the Czech Republic for her dissertation – Steroid Analysis Using Modern Chromatographic and Mass Spectrometry Techniques: From Fundamental Studies to Targeted Bioanalytical Applications (supervisor: Lucie Nováková, Charles University).&nbsp;<h5>What makes this field particularly exciting or unique in your view?</h5>What I&nbsp;enjoy about analytical chemistry is that, to a&nbsp;certain extent, it is a&nbsp;kind of detective work. You are often looking for ways to “make the invisible visible”. In other words, extract the information you are interested in from a&nbsp;complex sample and then interpret it correctly. What also appeals to me about bioanalytical chemistry is its interdisciplinary nature. It brings together analytical chemistry, biochemistry, biology and medicine, which means that you need to be able not only to translate a&nbsp;biological or clinical question into a&nbsp;measurable analytical experiment, but also to place the resulting data back into a&nbsp;broader biological context. This combination of different perspectives is probably what I&nbsp;enjoy most about the field. At the same time, there is still plenty of room for fundamental research, ranging from studying analytical techniques themselves and improving them to developing new methodological approaches.<h5>How did you end up at the <a target="_blank" rel="noopener noreferrer" href="https://mbu.cas.cz/en/research/laboratory-of-antibiotic-resistance-and-microbial-metabolomics">Laboratory of Antibiotic Resistance and Microbial Metabolomics</a>, and what project are you currently working on?</h5>I came to the Institute of Microbiology through a&nbsp;joint project between Dr Zdeněk Kameník and Assoc. Prof. Jan Bobek from the First Faculty of Medicine, Charles University. For me, it was also an opportunity to move from targeted analysis and the study of chromatographic techniques towards untargeted metabolomics and new biological questions.In the project, we are trying to identify new biologically active compounds that would be effective, particularly against pathogenic fungi. As a&nbsp;potential source of such compounds, we study streptomycetes, bacteria known for their ability to produce a&nbsp;wide range of biologically active compounds, including many antibiotics that are currently in clinical use. We focus on less-explored host-associated streptomycetes, in which we had already observed antifungal activity in previous experiments. We are especially interested in strains active against Candida albicans whose activity cannot be explained by the presence of a&nbsp;known bioactive compound. These strains may represent an interesting source of novel compounds. We then integrate the results of untargeted metabolomic analyses with genomic analyses, which allows us to obtain a&nbsp;more comprehensive view of the biosynthetic potential of selected strains.<h5>You also took part in this year’s Vědafest, a&nbsp;science outreach event for the public. What was it like?</h5>I already had some experience with science outreach through events such as Researchers’ Night and the Science Fair at my previous institution, but this year’s Vědafest was still new to me in some ways. This time, I&nbsp;was presenting a&nbsp;field that I&nbsp;myself had entered only relatively recently. It was therefore more challenging to find the right analogies and explain the essence of the topic in a&nbsp;way that was simple, yet precise and scientifically accurate. At the same time, that was exactly what made it inspiring. It forces you to look at your own work from a&nbsp;different perspective. What I&nbsp;enjoyed most was the spontaneity and curiosity of the children, who often came up with questions that would never even occur to an adult.<h5>What are the biggest challenges you face on your scientific journey, and what helps you overcome them?</h5>One of the greatest, but at the same time most interesting, challenges is, in my view, the uncertainty that is inseparably linked to research. For a&nbsp;long time, you often do not know whether you have taken the right direction in addressing a&nbsp;particular question or whether you will ultimately manage to find that figurative final piece of the puzzle. At the same time, this uncertainty is precisely what makes science exciting for me.Another major challenge, particularly in interdisciplinary projects, is communication. It is important from the very formulation of a&nbsp;hypothesis and the planning of experiments through to the interpretation of results, including negative ones, and placing them in a&nbsp;broader context. To some extent, every field has its own language, and finding a&nbsp;common understanding is not always straightforward. Personally, I&nbsp;find it very helpful to be able to discuss problems with colleagues on an ongoing basis, whether individually or during regular laboratory seminars. One of the major strengths of our current group is its interdisciplinary nature, which allows me to look at the same problem from several different perspectives. It is also important for me not to lose my curiosity, because that is ultimately what leads us to ask further questions.<h5>What are your plans after completing your PhD?</h5>After finishing my PhD, I&nbsp;decided that I&nbsp;do not need to have everything that comes next precisely mapped out straight away. I&nbsp;would like to keep different options open for a&nbsp;while and continue building on my experience in analytical chemistry, while at the same time connecting it with other areas that have a&nbsp;biological or medical relevance. I&nbsp;believe that we can keep learning throughout our lives, so I&nbsp;am quite curious to see where the next stage of my journey will take me.Thank you for the interview!

Interview: What Drew Postdoc Taťána Gazárková to Analytical Chemistry

Per- and polyfluoroalkyl substances (PFAS) have earned the moniker "forever chemicals" due to their extreme persistence in the environment. Their detection is crucial for protecting public health and the environment as these synthetic compounds continue to pose significant challenges worldwide. This comprehensive exploration examines why PFAS detection matters, current detection methods, and future directions in addressing PFAS contamination.<h3>Understanding PFAS and Their Health Impacts</h3>PFAS are a class of synthetic organic compounds with diverse structures, properties, and uses. Despite their diversity, all PFAS contain perfluoroalkyl moieties that are extremely resistant to environmental and metabolic degradation [1]. This high persistence is a defining characteristic that makes PFAS management particularly challenging.<h3>Documented Health Effects</h3>Current scientific research has linked PFAS exposure to numerous adverse health outcomes:<ul><li>Reproductive effects including decreased fertility and increased high blood pressure in pregnant women [8]</li><li>Developmental effects in children such as low birth weight, accelerated puberty, and behavioral changes [8]</li><li>Reduced immune system function, including decreased vaccine response</li><li>Interference with natural hormones and endocrine disruption</li><li>Increased cholesterol levels and obesity risk</li><li>Increased risk of several cancers, including prostate, kidney, testicular, oral cavity/pharynx, brain, and endocrine cancers [3]</li></ul>A 2023 study linked PFAS-contaminated water with up to a 33% increase in cancer incidence in affected areas [3]. The study compared regions with elevated PFAS levels to cancer data from the National Cancer Institute, finding higher incidences of various cancers after controlling for factors like smoking and obesity.<h3>Environmental Persistence and Contamination</h3>The extreme persistence of PFAS represents a fundamental concern for environmental management. PFAS are considered the most environmentally persistent substances among organic chemicals [7]. This persistence means that even if all PFAS uses were immediately phased out, existing contamination would continue to affect ecosystems and water supplies for generations.A 2023 study at a military fire training site estimated that PFAS contamination will persist for centuries without remediation [7]. The research found that terminal PFAS still exceed regulatory limits by 2000-fold decades after aqueous film-forming foam (AFFF) use ceased, with precursors accounting for around half of the extractable organofluorine across years.<h3>Current Detection Methods</h3><h4>EPA Standardized Methods</h4>The Environmental Protection Agency (EPA) has developed several standardized methods for PFAS detection, each with specific applications and capabilities:<h5>EPA Method 533</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/epa-533-drying-down-pfas-samples-after-spe">EPA Method 533</a> focuses on "short chain" PFAS with carbon chain lengths of C4 to C12. Released in December 2019, this method complements Method 537.1 and includes several key features:<ul><li>Uses isotope dilution quantification approach with extracted internal standards, which reduces overall analytical uncertainty</li><li>Employs weak anion exchange solid phase extraction cartridges as opposed to polystyrene divinylbenzene used in 537.1</li><li>Can analyze 25 PFAS compounds, including additional short-chain PFAS that were not apart of Method 537.1</li><li>Allows for longer holding times: 28 days to extraction and 28 days to analyze (compared to 14 days to extraction in Method 537.1)</li><li>Uses ammonium acetate as a preservative (versus Trisma in Method 537.1) [1]</li></ul><h5>EPA Method 537/537.1</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/sample-concentration-epa-method-537-pfas-determination">EPA Method 537 </a>was first published in 2009 for the determination of 14 PFAS in drinking water [6]. It was later updated to Method 537.1 in 2018 (with editorial updates in 2020) to expand its capabilities:<ul><li>Uses<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/what-is-solid-phase-extraction-spe"> solid phase extraction (SPE) </a>and<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis"> liquid chromatography/tandem mass spectrometry (LC-MS/MS)</a></li><li>Method 537.1 expanded detection to 18 PFAS compounds, including HFPO-DA (one component of GenX technology)</li><li>Utilizes styrene-divinylbenzene (SDVB) media for extraction</li><li>Requires samples to be extracted within 14 days and analyzed within 28 days</li><li>Methanol is used to elute the extracts. This should then be reconstituted with a 96:4 methanol:water mixture [1]</li></ul>Together, Methods 533 and 537.1 can detect a total of 29 unique PFAS compounds in drinking water and are approved for monitoring under the fifth Unregulated Contaminant Monitoring Rule (UCMR 5) and the PFAS National Primary Drinking Water Regulation [1] [3].<h5>EPA Method 1633</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/preparing-diverse-sample-matrices-for-epa-method-1633">EPA Method 1633</a>, released in 2024, represents a significant advancement in PFAS analysis:<ul><li>Developed for the analysis of 40 PFAS compounds in various matrices, including surface water, groundwater, wastewater, soil, biosolids, sediment, landfill leachate, and fish tissue</li><li>Expands beyond the drinking water focus of Methods 533 and 537.1</li><li>Provides a standardized approach that may replace modified drinking water methods (i.e., modified EPA 537) that were previously used for non-drinking water matrices [1]</li></ul><h4>Conventional Analytical Techniques</h4>The gold standard for PFAS analysis involves chromatographic techniques coupled with mass spectrometry:<ul><li>Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is the most widely used method for PFAS analysis, offering high sensitivity and specificity [1]</li><li>High-Resolution Mass Spectrometry (HRMS) allows for rapid detection and identification of PFAS species at very low concentrations [5]</li></ul>These techniques can detect PFAS at parts per trillion (ppt) levels, which is essential given the low concentrations at which PFAS can cause health effects [1]. However, these methods require sophisticated equipment, specialized training, and significant financial resources, making them inaccessible in many regions, particularly in developing countries.<h4>Emerging Detection Technologies</h4>Several innovative approaches are being developed to address the limitations of conventional methods:<ul><li>Electrochemical biosensors using modified electrodes have shown promise for selective PFAS detection with low detection limits [2]</li><li>Surface-Enhanced Raman Spectroscopy (SERS) uses metallic nanoparticles and can be made into a portable method for on-site testing [1]</li><li>Molecular imprinted polymers (MIPs) offer thermal and physical stability, reusability, and low-cost synthesis for PFAS detection [6]</li></ul>These emerging technologies aim to provide more accessible, field-deployable, and cost-effective alternatives to traditional laboratory-based methods.<h3>Challenges in PFAS Detection</h3><h4>Analytical Challenges</h4>Detecting PFAS presents several technical challenges:<ul><li>The ubiquity of PFAS in laboratory equipment and accessories can lead to background contamination when measuring at parts-per-trillion levels [1]</li><li>Many components in liquid chromatographs, mass spectrometers, and solid-phase extraction systems contain materials that can leach PFAS compounds [9]</li><li>The vast number of PFAS (thousands of compounds) makes comprehensive detection difficult, as analytical standards are only available for a small subset [1]</li><li>Complex matrices like food and environmental samples require sophisticated sample preparation techniques</li></ul><h4>Global Disparities in Detection Capabilities</h4>Access to PFAS detection technology varies significantly worldwide:<ul><li>Many developing regions, particularly in Africa, lack adequately equipped laboratories with the necessary instrumentation to detect and measure PFAS</li><li>There is often a scarcity of qualified professionals with experience in PFAS analysis in these regions</li><li>The high cost of acquiring and maintaining sophisticated analytical instruments presents a substantial obstacle to conducting extensive PFAS investigations in resource-limited settings [1]</li><li>Competing priorities such as infectious diseases, poverty, and food security often divert attention and resources from environmental pollutants like PFAS</li></ul><h4>Regulatory Landscape and Compliance</h4>The regulatory framework for PFAS is evolving rapidly worldwide:<ul><li>The EPA finalized Section 8(a)(7) of the Toxic Substances Control Act in September 2024, requiring manufacturers and importers to report on their use of PFAS since 2011 [10]</li><li>Electronic reporting for PFAS will open on July 11, 2025, with final reporting deadlines in 2026</li><li>Companies must report detailed information including chemical identity, production volumes, industrial and consumer products, worker exposure, and disposal methods [10]</li></ul>These regulations are driving demand for more effective and accessible PFAS detection methods to ensure compliance and protect public health.<h3>Future Directions in PFAS Detection</h3><h4>Technological Advancements</h4>The future of PFAS detection lies in developing more accessible, sensitive, and comprehensive methods:<ul><li>Non-targeted screening methods that can identify unknown PFAS compounds without requiring analytical standards for each specific compound</li><li>Total fluorine analysis techniques like Adsorbable Organic Fluorine and Total Oxidizable Precursor Assay that can quantify the presence of fluorine atoms within a sample [1]</li><li>Portable sensors and field-deployable technologies that enable on-site monitoring and rapid response to contamination events</li><li>AI-driven solutions that can improve data analysis and interpretation for complex PFAS mixtures</li></ul><h4>Collaborative Approaches</h4>Addressing the global challenge of PFAS detection requires coordinated efforts:<ul><li>International partnerships between researchers in developed and developing regions to enhance expertise and capacity building</li><li>Standardization of analytical methods to ensure consistency and comparability of results across different laboratories and regions</li><li>Open data sharing and collaboration across countries to leverage collective knowledge and resources</li><li>Integration of PFAS monitoring into broader environmental and public health surveillance systems</li></ul><h3>Conclusion</h3>The detection of PFAS is not merely a technical challenge but a critical public health and environmental imperative [1]. As these "forever chemicals" continue to persist in our environment, developing effective, accessible, and comprehensive detection methods becomes increasingly important. By advancing detection technologies, strengthening regulatory frameworks, and fostering global collaboration, we can better understand, monitor, and ultimately mitigate the impacts of PFAS contamination.The EPA's standardized methods (533, 537.1, and 1633) provide crucial tools for monitoring PFAS in various environmental matrices, but continued innovation is needed to address the full spectrum of PFAS compounds and to make detection more accessible globally [1] [6]. The path forward requires sustained investment in research and development, capacity building in resource-limited settings, and a commitment to environmental justice that ensures all communities have access to the tools and information needed to protect themselves from PFAS exposure. Only through such comprehensive approaches can we hope to address the complex challenges posed by these persistent pollutants.Be sure to check out our other installments of our&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/introducing-our-environmental-contaminants-series-making-sense-of-the-alphabet-soup">Environmental Contaminant Series</a>&nbsp;covering&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-persistent-organic-pollutants-pops">Persistent Organic Pollutants (POPs)</a>,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-polycyclic-aromatic-hydrocarbons-pahs">Polycyclic Aromatic Hydrocarbons (PAHs)</a>,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-semi-volatile-organic-compounds-svocs">Semi-Volatile Organic Compounds (SVOCs)</a>, and <a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-polychlorinated-biphenyls-pcbs">Polychlorinated Biphenyls (PCBs)</a>.

The Importance of Detecting Per- and Polyfluoroalkyl Substances (PFAS)

News from LabRulezLCMS Library - Week 36, 2026

Article

Application

Scientists

Environment

Water

Interview

The Czech Academy of Sciences (CAS) was established by Act No. 283/1992 Coll. as the Czech successor of the former Czechoslovak Academy of Sciences. It is set up as a complex of 54 public research institutions.

Czech Academy of Sciences

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Endotoxin analysis

LAL analysis for detection and quantification of bacterial endotoxins in liquid solutions and lyophilised samples, with results reported in EU/ml or EU/vial.

The Endotoxin Analysis is a laboratory test designed to detect and quantify bacterial endotoxins in suitable samples using the LAL (Limulus Amebocyte Lysate) assay.The analysis is intended for liquid solutions and lyophilised samples in vials. Results are reported in endotoxin units (EU), either per vial or per millilitre depending on the sample format.<h4>About Endotoxins</h4>Endotoxins are lipopolysaccharides (LPS) found in the outer membrane of Gram-negative bacteria. They can remain present even after bacterial cells are no longer viable and are therefore an important quality and safety parameter for pharmaceutical and laboratory products.The LAL assay is widely used for the detection and quantification of bacterial endotoxins due to its high sensitivity.<h4>Key Features</h4><ul><li>Detection and quantification of bacterial endotoxins</li><li>Analysis by LAL assay</li><li>Suitable for liquid solutions and lyophilised samples in vials</li><li>Results for lyophilised samples reported in EU/vial</li><li>Results for liquid solutions reported in EU/ml</li><li>Minimum sample amount of 1 ml solution or 1 vial</li><li>Standard analysis accurately quantifies values up to 10 EU/vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Testing method: LAL assay</li><li>Amount of sample required: 1 ml solution or 1 vial</li><li>Result format for vial with lyophilisate: EU/vial</li><li>Result format for liquid solution: EU/ml</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>The standard endotoxin analysis provides accurate results for values up to 10 EU/vial. Values above 10 EU/vial are estimated.</li><li>If a fully quantitative result above this range is required, an additional test using another vial and an appropriate dilution is necessary. Sending two vials is therefore recommended when elevated endotoxin levels may be expected.</li><li>If values above 10 EU/vial are expected in advance, this should be communicated before testing so that the sample can be analysed using an appropriately calibrated procedure.</li><li>Endotoxin analysis is not offered for oils, raw API powders, tablets, or capsules.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

Clenbuterol Analysis

Targeted HPLC analysis of clenbuterol in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Clenbuterol Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clenbuterol in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Clenbuterol</h4>Clenbuterol is a synthetic beta-2 adrenergic agonist with bronchodilator activity. It stimulates beta-2 adrenergic receptors and can affect smooth muscle tone, cardiovascular function, and metabolic processes.Clenbuterol has been used therapeutically in some countries for respiratory conditions, but it is not approved for human use in many jurisdictions. It is also known for non-medical use related to its stimulant and metabolic effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of clenbuterol</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Clenbuterol</li><li>Other name: Clen</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for clenbuterol. It does not automatically screen the sample for other beta-2 agonists, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of clenbuterol required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Dihexa analysis

HPLC analysis of Dihexa for identification, amount and purity in tablets, capsules, lyophilized samples and raw API powders, with optional solvent selection.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Dihexa in tablets, capsules, lyophilized samples and raw API powders. HPLC testing provides information about the target compound content and its purity relative to chromatographically detectable impurities.<h4>Dihexa</h4>Dihexa is a synthetic peptide-derived compound with the sequence Hexanoyl-Tyr-Ile-Ahx-NH2. Its molecular weight is approximately 504 Da.An important consideration in Dihexa analysis is its limited solubility in water. The choice of solvent can therefore significantly affect how much of the compound enters solution and can subsequently be measured by HPLC. Water is used as the standard preparation procedure for lyophilized samples, while DMSO and methanol are available as alternative solvents.<h5>What the Analysis Determines</h5><ul><li>Identity of Dihexa</li><li>Amount of Dihexa in the sample</li><li>Peptide purity</li><li>Dihexa content per tablet or capsule</li><li>Dihexa content in mg per vial for lyophilized samples</li><li>Optional m/m purity for raw API powders</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: Dihexa</li><li>CAS number: 1401708-83-5</li><li>Molecular weight: 504 Da</li><li>Sequence: Hexanoyl-Tyr-Ile-Ahx-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for oral products: mg per tablet or capsule and peptide purity</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum oral sample: 3 tablets or capsules</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Default solvent for lyophilized samples: water</li><li>Optional solvents: DMSO or methanol</li><li>Average turnaround time: 7 business days</li></ul><h4>Important Notice – Dihexa Solubility</h4>Dihexa has limited solubility in water, which must be considered particularly when analyzing lyophilized samples.<h5>Water – Standard Procedure</h5>Water is the default solvent used for standard sample preparation. However, Dihexa is poorly soluble in water. Insoluble particles are removed by filtration before HPLC analysis because only material transferred into solution can be analyzed.If part of the Dihexa remains undissolved, it may be removed during filtration and the measured concentration may therefore be lower than the total amount originally present in the sample.<h5>DMSO</h5>DMSO provides improved dissolution of Dihexa and reduces potential losses caused by removing insoluble particles before analysis. When DMSO is selected, the prepared solution is intended for analytical testing only.<h5>Methanol</h5>Methanol provides very good dissolution of Dihexa and is suitable when maximizing extraction of the target compound before HPLC analysis is required. The resulting solution is likewise intended for analytical testing only.For tablets and capsules, the standard analytical procedure is recommended.The alternative m/m purity result format is intended exclusively for raw API powders.<h4>Additional Analyses</h4><h5>Solvent – Methanol</h5><ul><li>Methanol can be used instead of the standard aqueous preparation procedure. Its improved ability to dissolve Dihexa can reduce losses associated with removal of insoluble material.</li></ul><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Solvent – DMSO</h5><ul><li>DMSO can be used to dissolve Dihexa before analysis. This option can improve transfer of the target compound into solution and reduce losses during filtration.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

DSIP analysis

HPLC analysis of DSIP for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of DSIP in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its purity relative to chromatographically detectable impurities.<h4>DSIP</h4>DSIP, or Delta Sleep-Inducing Peptide, is a short peptide composed of nine amino acid residues. It is also known as Sleep-Promoting Peptide.Its sequence is H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH, and its molecular weight is approximately 849 Da.HPLC analysis confirms the presence of DSIP in the sample, determines its amount and evaluates peptide purity.<h5>What the Analysis Determines</h5><ul><li>Identity of DSIP</li><li>Amount of DSIP in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: DSIP</li><li>Other names: Delta Sleep-Inducing Peptide, Sleep-Promoting Peptide</li><li>CAS number: 62568-57-4</li><li>Molecular weight: 849 Da</li><li>Sequence: H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of DSIP in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Elamipretide (SS-31) Analysis

HPLC analysis of Elamipretide (SS-31) for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Elamipretide (SS-31) in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its purity relative to chromatographically detectable impurities.<h4>Elamipretide (SS-31)</h4>Elamipretide, also known as SS-31, is a synthetic mitochondria-targeting tetrapeptide. Its structure contains alternating basic and aromatic amino acid residues, and research has particularly investigated its interactions with mitochondrial membranes and mitochondrial bioenergetics.Its peptide sequence is H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2 and includes D-arginine and the modified amino acid 2,6-dimethyltyrosine. Elamipretide is also widely referred to as SS-31.HPLC analysis confirms the presence of SS-31 in the sample, determines its amount and evaluates peptide purity.<h5>What the Analysis Determines</h5><ul><li>Identity of Elamipretide (SS-31)</li><li>Amount of Elamipretide in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: SS-31</li><li>Other name: Elamipretide</li><li>CAS number: 736992-21-5</li><li>Sequence: H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of Elamipretide in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Epithalon Analysis

HPLC analysis of Epithalon for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Epithalon in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its purity relative to chromatographically detectable impurities.<h4>Epithalon</h4>Epithalon, also known as Epitalon, is a short synthetic tetrapeptide composed of four amino acid residues. Its sequence is H-Ala-Glu-Asp-Gly-OH, and its molecular weight is approximately 390 Da.This analysis is specifically intended for standard Epithalon. Other variants or modified forms, such as NA Epithalon, are not the target compound of this method and require an appropriate separate analysis.HPLC analysis confirms the presence of Epithalon in the sample, determines its amount and evaluates peptide purity.<h5>What the Analysis Determines</h5><ul><li>Identity of Epithalon</li><li>Amount of Epithalon in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: Epithalon</li><li>Other name: Epitalon</li><li>CAS number: 64082-79-7</li><li>Molecular weight: 390 Da</li><li>Sequence: H-Ala-Glu-Asp-Gly-OH</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>Before ordering the analysis, make sure that the sample contains standard Epithalon. Other variants, such as NA Epithalon, are not the target compound of this test.The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of Epithalon in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

FOXO4-DRI Analysis

HPLC analysis of FOXO4-DRI for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of FOXO4-DRI, also referred to as FOX04-DRI, in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its purity relative to chromatographically detectable impurities.<h4>FOXO4-DRI</h4>FOXO4-DRI is a synthetic peptide with a molecular weight of approximately 5,358 Da. Its sequence contains 46 amino acid residues and includes a highly basic C-terminal region rich in arginine and lysine residues.HPLC analysis confirms the presence of FOXO4-DRI in the sample, determines its amount and evaluates peptide purity.<h5>What the Analysis Determines</h5><ul><li>Identity of FOXO4-DRI</li><li>Amount of FOXO4-DRI in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: FOXO4-DRI</li><li>Other name: FOX04-DRI</li><li>CAS number: 2460055-10-9</li><li>Molecular weight: 5,358 Da</li><li>Sequence: Leu-Thr-Leu-Arg-Lys-Glu-Pro-Ala-Ser-Glu-Ile-Ala-Gln-Ser-Ile-Leu-Glu-Ala-Tyr-Ser-Gln-Asn-Gly-Trp-Ala-Asn-Arg-Arg-Ser-Gly-Gly-Lys-Arg-Pro-Pro-Pro-Arg-Arg-Arg-Gln-Arg-Arg-Lys-Lys-Arg-Gly-OH</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of FOXO4-DRI in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

GHRP-2 Analysis

HPLC analysis of GHRP-2 for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of GHRP-2 in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its purity relative to chromatographically detectable impurities.<h4>GHRP-2</h4>GHRP-2, or Growth Hormone Releasing Peptide-2, is a synthetic peptide composed of six amino acid residues. It is also known as Growth Hormone Secretagogue 2.Its sequence is H-D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2 and contains several modified amino acid residues, including D-alanine, D-2Nal and D-phenylalanine. The molecular weight of GHRP-2 is approximately 818 Da.HPLC analysis confirms the presence of GHRP-2 in the sample, determines its amount and evaluates peptide purity.<h5>What the Analysis Determines</h5><ul><li>Identity of GHRP-2</li><li>Amount of GHRP-2 in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: GHRP-2</li><li>Other names: Growth Hormone Releasing Peptide-2, Growth Hormone Secretagogue 2</li><li>CAS number: 158861-67-7</li><li>Molecular weight: 818 Da</li><li>Sequence: H-D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of GHRP-2 in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

GHRP-6 Analysis

HPLC analysis of GHRP-6 for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of GHRP-6 in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its purity relative to chromatographically detectable impurities.<h5>GHRP-6</h5>GHRP-6, or Growth Hormone Releasing Peptide-6, is a synthetic peptide composed of six amino acid residues. It is also known as Growth Hormone Secretagogue 6.Its sequence is H-DL-His-DL-Trp-DL-Ala-DL-Trp-DL-Phe-DL-Lys-NH2, and its molecular weight is approximately 873 Da.HPLC analysis confirms the presence of GHRP-6 in the sample, determines its amount and evaluates peptide purity.<h5>What the Analysis Determines</h5><ul><li>Identity of GHRP-6</li><li>Amount of GHRP-6 in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h5>Analysis Parameters</h5><ul><li>Target compound: GHRP-6</li><li>Other names: Growth Hormone Releasing Peptide-6, Growth Hormone Secretagogue 6</li><li>CAS number: 87616-84-0</li><li>Molecular weight: 873 Da</li><li>Sequence: H-DL-His-DL-Trp-DL-Ala-DL-Trp-DL-Phe-DL-Lys-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of GHRP-6 in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Estradiol Blind Screening

Blind HPLC screening of estradiol and selected estradiol esters in oil samples and raw API powders, including identification and quantification of mixtures.

The Estradiol Blind Screening is a targeted laboratory test designed to identify and quantify estradiol and selected estradiol esters in oil-based samples and raw active pharmaceutical ingredient (API) powders.With blind testing, the specific estradiol ester does not need to be declared in advance. All target compounds included in the analysis are screened, identified, and quantified, including mixtures containing more than one estradiol form.<h4>About Estradiol and Estradiol Esters</h4>Estradiol is a naturally occurring estrogen hormone. Esterification of estradiol produces derivatives with different physicochemical and pharmacokinetic properties.This screening covers estradiol without an ester as well as several commonly encountered estradiol esters, including benzoate, cypionate, enanthate, undecylenate, and valerate. Estradiol hemihydrate is also included in the screening.<h4>Key Features</h4><ul><li>Blind identification and quantification of estradiol and selected estradiol esters</li><li>No need to specify the expected ester before testing</li><li>Detection of multiple estradiol forms within mixtures</li><li>Suitable for oil-based samples and raw API powders</li><li>Analysis by HPLC</li><li>Results for oil samples reported in mg/ml</li><li>Alternative results for raw API powders reported as percentage content</li><li>Minimum sample amount of 0.5–1 ml for oil samples</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: Estradiol hemihydrate, Estradiol benzoate, Estradiol cypionate, Estradiol enanthate, Estradiol no ester, Estradiol undecylenate, Estradiol valerate</li><li>Testing method: HPLC</li><li>Result format for oil samples: mg/ml</li><li>Alternative result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oil samples: 0.5–1 ml of oil</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Due to limitations of the analytical method, estradiol hemihydrate will be identified as estradiol no ester (estradiol base).</li><li>The analysis covers only the estradiol forms listed in the analysis parameters. It does not automatically screen the sample for other estrogens, related compounds, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Related content

The Importance of Detecting Per- and Polyfluoroalkyl Substances (PFAS)

Interview: What Drew Postdoc Taťána Gazárková to Analytical Chemistry

News from LabRulezLCMS Library - Week 36, 2026